Literature DB >> 20589720

RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

R Katherine Hyde1, P Paul Liu.   

Abstract

The core binding factor (CBF) acute myeloid leukemias (AMLs) are a prognostically distinct subgroup that includes patients with the inv(16) and t(8:21) chromosomal rearrangements. Both of these rearrangements result in the formation of fusion proteins, CBFB-MYH11 and AML1-ETO, respectively, that involve members of the CBF family of transcription factors. It has been proposed that both of these fusion proteins function primarily by dominantly repressing normal CBF transcription. However, recent reports have indicted that additional, CBF-repression independent activities may be equally important during leukemogenesis. This article will focus on these recent advances. Published 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20589720      PMCID: PMC3298446          DOI: 10.1002/jcb.22596

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  57 in total

1.  Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis.

Authors:  B A Van der Reijden; L de Wit; S van der Poel; E B Luiten; M Lafage-Pochitaloff; N Dastugue; J Gabert; B Löwenberg; J H Jansen
Journal:  Hematol J       Date:  2001

2.  Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha.

Authors:  Y Y Tang; J Shi; L Zhang; A Davis; J Bravo; A J Warren; N A Speck; J H Bushweller
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

Review 3.  Core-binding factors in haematopoiesis and leukaemia.

Authors:  Nancy A Speck; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

4.  The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.

Authors:  B Lutterbach; Y Hou; K L Durst; S W Hiebert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.

Authors:  G Huang; K Shigesada; K Ito; H J Wee; T Yokomizo; Y Ito
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

6.  AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Authors:  T Pabst; B U Mueller; N Harakawa; C Schoch; T Haferlach; G Behre; W Hiddemann; D E Zhang; D G Tenen
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.

Authors:  R Katherine Hyde; Yasuhiko Kamikubo; Stacie Anderson; Martha Kirby; Lemlem Alemu; Ling Zhao; P Paul Liu
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

10.  The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Authors:  Bryan Linggi; Carsten Müller-Tidow; Louis van de Locht; Ming Hu; John Nip; Hubert Serve; Wolfgang E Berdel; Bert van der Reijden; Dawn E Quelle; Janet D Rowley; John Cleveland; Joop H Jansen; Pier Paolo Pandolfi; Scott W Hiebert
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

View more
  8 in total

1.  HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.

Authors:  Lisa E Richter; Yiqian Wang; Michelle E Becker; Rachel A Coburn; Jacob T Williams; Catalina Amador; R Katherine Hyde
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

Review 2.  Dynamics of epigenetic modifications in leukemia.

Authors:  Iris Uribesalgo; Luciano Di Croce
Journal:  Brief Funct Genomics       Date:  2011-01-21       Impact factor: 4.241

3.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.

Authors:  Lea Cunningham; Steven Finckbeiner; R Katherine Hyde; Noel Southall; Juan Marugan; Venkat R K Yedavalli; Seameen Jean Dehdashti; William C Reinhold; Lemlem Alemu; Ling Zhao; Jing-Ruey Joanna Yeh; Raman Sood; Yves Pommier; Christopher P Austin; Kuan-Teh Jeang; Wei Zheng; Paul Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-21       Impact factor: 11.205

4.  Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.

Authors:  Daniel J Trombly; Troy W Whitfield; Srivatsan Padmanabhan; Jonathan A R Gordon; Jane B Lian; Andre J van Wijnen; Sayyed K Zaidi; Janet L Stein; Gary S Stein
Journal:  BMC Genomics       Date:  2015-04-17       Impact factor: 3.969

5.  Genetic deletion of Sphk2 confers protection against Pseudomonas aeruginosa mediated differential expression of genes related to virulent infection and inflammation in mouse lung.

Authors:  David L Ebenezer; Panfeng Fu; Yashaswin Krishnan; Mark Maienschein-Cline; Hong Hu; Segun Jung; Ravi Madduri; Zarema Arbieva; Anantha Harijith; Viswanathan Natarajan
Journal:  BMC Genomics       Date:  2019-12-16       Impact factor: 3.969

6.  Novel insights into the genetic controls of primitive and definitive hematopoiesis from zebrafish models.

Authors:  Raman Sood; Paul Liu
Journal:  Adv Hematol       Date:  2012-07-25

7.  MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.

Authors:  Nicole Kohrs; Stephan Kolodziej; Olga N Kuvardina; Julia Herglotz; Jasmin Yillah; Stefanie Herkt; Alexander Piechatzek; Gabriela Salinas Riester; Thomas Lingner; Christian Wichmann; Halvard Bonig; Erhard Seifried; Uwe Platzbecker; Hind Medyouf; Manuel Grez; Jörn Lausen
Journal:  PLoS Genet       Date:  2016-03-18       Impact factor: 5.917

Review 8.  Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.

Authors:  Lisa Richter; Yiqian Wang; R Katherine Hyde
Journal:  Oncotarget       Date:  2016-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.